Nov 21, 2025 1:26 PM Eastern Standard Time Deadline Approaching: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Share BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 16, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Perrigo Company plc ("Perrigo†or the "Company†) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclus ...

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

Market Overview - The ASX is expected to open with a 25-point increase, influenced by positive sentiment from U.S. markets amid hopes of a government shutdown resolution [1] - The U.S. economy has faced stagnation during the shutdown, but optimism is beginning to emerge [2] U.S. Market Sentiment - Wall Street shows excitement following President Trump's announcement of potential $2,000 payouts funded by tariffs, although details remain unclear [3] - All three major U.S. indexes ended Week 44 lower, with the Nasdaq dropping 3% and the S&P 500 declining by 1.6% [3] Australian Economic Indicators - Key statistics to watch this week include Westpac's and NAB's consumer confidence reports, along with Australian employment figures [4] Company News - ANZ Group (ASX:ANZ) reports a 14% decline in cash profits due to redundancy costs, legal penalties, and intense competition in retail banking [5] - A2 Milk (ASX:A2M) is expanding its partnership with China State Farm to include English-label infant formula for eCommerce [5] - Woodside Energy (ASX:WDS) faces a potential strike at its $12.5 billion Pluto LNG facility expansion, with 2,000 workers voting for wage increases [6] - Moho Resources (ASX:MOH) has commenced its first drilling at the Bush Chook project [6] - Barrenjoy has raised the target price for James Hardie (ASX:JHX) to $31 [6] Commodity Market - The Australian dollar is trading at 64.8 U.S. cents [7] - Iron Ore prices have decreased by 2.4% to $101.45 per tonne, while Brent Crude has seen a slight increase of 0.4% to $63.63 per barrel [7] - Gold remains stable at $4,005 per ounce, and U.S. natural gas futures have dropped by 1% to $4.31 per gigajoule [7]

Core Viewpoint - Perrigo Company plc (NYSE:PRGO) has experienced significant stock decline, reaching a new 52-week low due to weak net sales and a strategic review of its infant formula business [1][3]. Financial Performance - Perrigo's stock fell to $15.05 during intra-day trading, ultimately closing at $15.10, reflecting a 25.21% decrease [2]. - The company's net sales decreased by 4% to $1.043 billion from $1.087 billion year-over-year, impacted by lower organic sales and divestitures [2]. - Despite the sales decline, Perrigo reported a net income of $7.5 million, a recovery from a $21 million net loss in the same period last year [3]. Strategic Review - Perrigo is conducting a strategic review of its infant formula business, which may lead to a potential sale [3]. - The review aims to ensure the company's portfolio is positioned for sustainable growth and free cash flow generation, as stated by the President and CEO Patrick Lockwood-Taylor [4]. - The company acknowledges that while its infant formula operations have stabilized, the changing external environment has made it less strategic in alignment with its consumer health OTC businesses [5].

Financial Data and Key Metrics Changes - For Q3 2025, organic net sales declined by 4.4%, impacted by a 1.6% decline from the global OTC business and a 2.8% decline from businesses under review [11][12] - Year-to-date, organic net sales decreased by 1.7%, primarily driven by a 0.8% impact from businesses under review and a 0.5% impact from the absence of last year's Opill launch stocking benefits [12][24] - Q3 EPS was $0.80, down one cent from the prior year, while year-to-date EPS grew 21% to $1.97 [11][21] Business Line Data and Key Metrics Changes - In the US OTC market, Perrigo gained volume share of 90 basis points across nearly every category, particularly in smoking cessation, allergy, and women's health [6][13] - The CSCI segment saw a 5.3% decline in organic net sales for Q3, primarily due to soft OTC category consumption trends, while year-to-date organic net sales grew by 0.7% [19][20] - The infant formula business experienced a 3.8% decline in Q3, with share recovery taking longer than expected [14][20] Market Data and Key Metrics Changes - US OTC volume consumption declined by 3.2%, while European OTC grew by only 0.6%, falling short of original assumptions [13][24] - The overall market consumption trends have been softer than anticipated, impacting Perrigo's net sales outlook by an estimated $150-$170 million [13][24] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, which has guided its actions and priorities [8][16] - A strategic review of the infant formula business is underway, with the aim to optimize its long-term role within the Perrigo portfolio [14][47] - The sale of the dermocosmetics business is on track to close in Q1 2026, with proceeds aimed at reducing leverage [23][47] Management's Comments on Operating Environment and Future Outlook - Management noted that the current consumption trends are dynamic and unpredictable, with expectations for stabilization in 2026 [41][46] - The company remains committed to deleveraging and sustaining dividends while focusing on high-potential OTC portfolio growth [15][47] - Management expressed confidence in Perrigo's ability to capture durable demand for consumer health solutions despite current challenges [17][46] Other Important Information - The company has achieved $163 million in gross annual savings from Project Energize, exceeding initial expectations [9][18] - Operating cash flow for Q3 was $52 million, with year-to-date cash flow at $63 million [22][23] Q&A Session Summary Question: Follow-up on infant formula share and expectations - Management acknowledged that while store brand share is growing, it is at a slower pace than anticipated due to competitive pressures and market dynamics [28][29] Question: Insights on OTC and infant formula consumption changes - Management noted that OTC consumption has been volatile, with a significant decline observed in Q3 compared to previous quarters [33][34] Question: Plans for reinvestment given current market conditions - Management indicated that while priorities remain on deleveraging and maintaining dividends, there may be opportunities to increase spending in high-performing areas [38][39] Question: Current share of infant formula and future growth expectations - Management reported an approximate 16% share in infant formula, with expectations to grow to 18-20% over the next 12 months [40][41] Question: Clarification on gross margin pressure - Management confirmed that the gross margin pressure was primarily due to sales deleverage and product mix, not input costs [42][43]

Core Insights - The infant formula market has been stagnant for decades, with little innovation despite changes in other consumer products [3][4] - The market is dominated by a few key players, primarily Reckitt and Abbott, who together hold nearly 70% of the market share as of 2022 [5] - A significant event, Abbott's formula manufacturing shutdown in 2022, highlighted the risks associated with market concentration and the implications for supply availability [6] Company Insights - Bobbie, co-founded by Laura Modi, aims to disrupt the infant formula industry by introducing innovative products and changing the cultural perceptions around infant feeding [1][2] - The company has a co-manufacturing relationship with Perrigo, which acquired Nestle's U.S. and Canada-based formula business in 2022 [5] Industry Insights - The infant formula market is characterized by a duopoly, with limited competition leading to a lack of innovation [4][5] - The Federal Trade Commission's report during the 2022 formula shortage underscored the vulnerabilities in the market structure and the need for increased competition [5][6]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, up by 4.1% [18] - The P&C segment saw a 15.5% growth, while the probiotic business experienced a decline of around 10% [9][19] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a growth driven by IMF sales and nutritional products [20] - The North American market grew by 4.6%, while the ANZ market saw a decline of 15.6% due to Daigou channel sales [20][21] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to maintain its number one position in the ANC market in China and expand into new markets [44][45] - Focus on premiumization and diversification strategies to enhance profitability and market share [46] - Continued investment in product innovation and consumer education to drive growth [15][44] Management Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of adapting strategies [3] - The company expects to achieve high single-digit sales growth for the full year, with a stable EBITDA margin around 15% [66] - Confidence in overcoming challenges from the Guo Biao transition and maintaining growth momentum [8][49] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - Main drivers include innovative products and penetration into new channels, with a focus on retail and online channels [70][71] Question: Will the IMF gross profit margin be restructured? - Adjustments are being made to improve profitability, with 80% of product categories returning to expected growth [72][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote domestic business growth to offset declines in the Daigou channel, maintaining guidance for the whole year [85][86]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, showing a 4.1% increase [18] - The P&C business globally saw a 14% growth, with SOLIGO returning to 17.5% growth [10][36] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a 13% growth in the ANC business [20][5] - The ANZ market experienced a 5.6% growth, while the North American market saw a 4.6% growth [7][38] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to diversify its market and brands while consolidating its core market [24] - Focus on premiumization and innovation in product offerings to drive growth [44][45] - Continued investment in new markets and channels to enhance profitability [46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of strategic adjustments [3] - The company remains confident in achieving high single-digit sales growth for the full year [66] - Future strategies include focusing on super premium segments and expanding into new markets [45][46] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - The main drivers include innovative products and penetration into new channels [70][71] Question: Will the product mix and brand be restructured strategically? - Yes, adjustments are being made to improve profitability, particularly in the non-core IMF and probiotic segments [71][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote growth in domestic channels to offset declines in the Daigou channel [85][87]

Industry Overview - The Chinese infant formula market is entering a new cycle focused on "quality first," driven by consumption upgrades and evolving parenting philosophies. Parents are shifting their focus from basic nutritional needs to comprehensive quality across the entire supply chain, including sourcing, formulation, production standards, and brand reputation [1][8] - The share of ultra-premium infant formula is expected to rise from 18% in 2025 to 35% by 2030, reflecting the increasing importance Chinese families place on infant nutrition and opening opportunities for global premium brands [1] Company Introduction - Bimbosan, a Swiss national infant formula brand with over 90 years of history, has officially entered the Chinese market, bringing a "pure and scientific" nutritional solution derived from the Alps. The brand emphasizes Swiss quality, professional heritage, and a commitment to parents and babies [1][8] Quality Control - Bimbosan's reputation as a trusted "national infant formula brand" is built on its comprehensive quality control across four dimensions: sourcing, production standards, and parenting philosophy, establishing a unique "Swiss standard" [2] - The milk source for Bimbosan comes from the pristine pastures of the Swiss Alps, providing a natural and pollution-free environment for dairy farming [3] Dairy Management - Bimbosan employs meticulous management practices for its dairy cows, ensuring each cow has a dedicated profile. The cows are fed a balanced diet of natural grasses and are not subjected to growth hormones or antibiotics, resulting in high-quality milk that is rich in nutrients and has a pleasant taste [4] Certification Standards - Bimbosan's standards exceed those of the EU, with its milk sources meeting Swiss dairy green standards and receiving Swissmilk Green certification. The organic series has dual organic certification from Switzerland and the EU, ensuring the formula is free from pollutants and additives [5] Nutritional Philosophy - Bimbosan's "building block nutrition" philosophy respects the individual growth rhythms of infants, providing tailored support based on their developmental stages. This approach allows for precise nutritional responses to each child's unique needs [6][7] - The product range includes a Super Premium series that meets specific developmental needs, an organic series for families seeking pure nutrition, and a goat milk series for infants with sensitive stomachs [7] Market Position - With over 90 years of experience, Bimbosan has established itself as a leader in the high-end organic infant formula sector, consistently ranking first in Swiss evaluations and maintaining a significant market share in Europe [8]

Financial Data and Key Metrics Changes - Organic net sales declined by 0.4%, but excluding lost distribution and prior year effects, organic net sales grew by 1.8% year over year [16][25] - Gross margin expanded by 440 basis points year over year to 41%, driven by business recovery in infant formula [16][25] - First quarter EPS increased by 107% year over year to $0.60 per share [16][28] Business Line Data and Key Metrics Changes - Infant formula net sales increased by 19% compared to the same quarter last year, contributing to overall recovery [7][19] - OTC brands achieved solid organic growth of 5.9% year over year, driven by strong sales of key products [10] - Operating income in the CSCI segment grew by 10% organically, while CSEA operating income grew by 90% due to infant formula recovery [27] Market Data and Key Metrics Changes - Dollar sales across self-care categories turned negative compared to the prior year, reflecting cautious consumer behavior due to inflation and reduced consumer confidence [11][12] - Total US OTC store brand volume gained 50 basis points over the last four weeks, indicating a shift in consumer buying patterns towards value-oriented products [15] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, with positive results from stabilizing key parts of the business [6][21] - The synergistic relationship between store brand and OTC brands is being leveraged to drive growth, with substantial cash flow generated from store brands [10] - The company is enhancing its new product development process to create a more efficient pipeline [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macroeconomic environment but expressed confidence in the company's positioning to navigate these challenges [12][22] - The company is widening its 2025 net sales projections due to macroeconomic uncertainties while reaffirming its adjusted EPS range [12][30] - Management expects a significant ramp-up in infant formula sales in the second half of the year due to new product introductions [39] Other Important Information - The company plans to offset tariff-related cost increases through strategic pricing actions and sourcing more manufacturing to US facilities [14][30] - The gross increase in global cost of goods sold from tariffs is expected to be approximately 5.5% for the full year [32] Q&A Session Summary Question: Impact of tariffs on EPS for 2026 - Management expects that actions taken to mitigate tariff impacts will offset any major changes in EPS projections for 2025 and beyond [36][37] Question: Sales ramp for infant formula - Management anticipates a similar sales trajectory in Q2, with significant growth expected in the second half due to new SKU introductions [38][39] Question: Contract manufacturing activity - There is an increase in activity for contract manufacturing as competitors seek domestic supply routes [44] Question: Organic sales performance - Organic sales were broadly in line with expectations, with upper respiratory products performing well despite some regional variances [48][49] Question: Gross margin expectations - Management maintains a full-year gross margin expectation of around 40%, despite better-than-expected Q1 performance [52][53] Question: Widening net sales range - The widening range reflects dynamic shifts in consumer behavior and ongoing opportunities in the market [60][62] Question: Pharma-specific tariffs impact - Management anticipates a potential $100 million impact from pharma-specific tariffs, with plans to mitigate through pricing and sourcing strategies [84][85]